KeyBanc raised the firm’s price target on BioLife Solutions (BLFS) to $33 from $30 and keeps an Overweight rating on the shares. BioLife, under its new CEO, has completed a quick succession of three asset sales, and the firm’s proforma models show a high-growth and high-margin business with its dominance of freeze media for the cell, gene, and CAR-T markets, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS:
- BioLife Solutions price target lowered to $27 from $29 at H.C. Wainwright
- BioLife Solutions (BLFS) Makes Promising Strategic Pivot
- BioLife Solutions announces $6.1M sale of freezer subsidiary, Arctic Solutions
- BioLife Solutions price target raised to $32 from $30 at Craig-Hallum
- BioLife Solutions price target raised to $30 from $28 at Lake Street